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The  two exocyclic oxygen atoms at phosphorus of 
cAMP have been repIaced by a sulfur atom or by a 
dimethylamino group. These substitutions introduce 
chirality  at  the phosphorus  atom; therefore,  two  dia- 
stereoisomers are known for each derivative: (Sp)- 
CAMPS, (Rp)-CAMPS, (Sp)-cAMPN(CH&, and Rp- 
cAMPN(CH&. We have  investigated  the  agonistic  and 
antagonistic  activities of these compounds in  four 
CAMP-dependent reactions:  activation of the  cellular 
slime mold Dictyostelium  discoideum via its cell sur- 
face cAMP receptor,  and phosphorylation by CAMP- 
dependent  protein  kinases  type I, type I1 (both mam- 
malian enzymes), and  type D (derived  from D. discoi- 
deum). The  results show that 1) the compounds (Sp)- 
CAMPS and (Sp)-cAMPN(CH& are (mostly full)  ago- 
nists  for  the  four  proteins.  Half-maximal  activation s 
at micromolar  concentrations (0.8-7 FM). 2) (Rp)- 
CAMPS is a full  antagonist  for  the  cell  surface  receptor 
and  protein  kinases  type I and 11, with  apparent  inhi- 
bition  constants  between 0.8 and 8 PM. This compound 
is a partial  agonist  for  protein  kinase  type D, where  it 
induces maximally 50% activation of the enzyme if 
compared  with CAMP. 3) (Rp)-cAMPN(CH& is a full 
antagonist  for  the  cell  surface  receptor,  and  for  protein 
kinase  type 11. This compound is a partial  agonist  for 
protein  kinase  type I (at least 50% activation if com- 
pared  with CAMP), and  inactive  for  protein  kinase  type 
D. This  derivative is at least 25-fold  less  active as  an 
antagonist  than (Rp)-CAMPS. 4 )  The  activity of mix- 
tures of different  concentrations of the  antagonist (Rp)- 
CAMPS with  different  concentrations of cAMP reveals 
that  the compound is a  competitive  antagonist of CAMP 
at micromolar  concentrations. 
cAMP  has  an  important  function  as a signal molecule in 
hormone  action  and cell communication.  During  the  last 20 
years more than 600 derivatives of cAMP have  been synthe- 
sized, with the  aim  to  find  compounds  with special  activities, 
such as nonhydrolyzable agonists or antagonists. The high 
number of derivatives prevents  the  screening of all  compounds 
in  many CAMP-dependent  reactions. Therefore, we have  used 
a different  approach (1-3) in which it  is  assumed  that  CAMP 
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article were defrayed in part by the payment of page charges. This 
article must therefore be hereby marked “advertisement” in accord- 
ance with 18 U.S.C. Section 1734 solely to indicate this fact. 
interacts with its receptor proteins via electrostatic forces, 
such as ionic interactions, hydrogen bonds, and hydrophobic 
interactions.  cAMP  can form all types of interactions. A set 
of derivatives has been selected, in which each derivative 
prevents only one of the possible interactions while the  other 
interactions  are minimally disturbed.  This  method allows to 
obtain  information  on  the major interactions between cAMP 
and  its receptor proteins by using  only 20 derivatives (4, 5 ) .  
Two types of experiments  are performed in  the  most  exten- 
sive studies. 1) The  inhibition of the  binding of [3H]cAMP to 
the  receptor  proteins by the derivatives  provides information 
on  the  atomic  interactions between the  cAMP molecule and 
the receptor protein. 2) The  activity of the receptor-effector 
complex at  saturating derivative concentrations provides in- 
formation  on  the  intrinsic  activity of the derivative; i.e. the 
extent  to which a  derivative can  activate when  all the receptor 
sites  are occupied with  derivative. These  studies  indicate  that 
essentially  all  derivatives of CAMP with  modifications  in the 
adenine, ribose, or cyclophosphate  moiety  fully activate  the 
receptor  (4, 5). Recently four new derivatives have been 
synthesized which show anomalous binding and activation 
profiles (4-6). In  these derivatives the two exocyclic oxygen 
atoms of the cyclophosphate moiety have been  replaced  by a 
sulfur  atom (7) or a dimethylamino group. These  substitutions 
introduce  chirality at  the  phosphorus  atom of cAMP yielding 
two stereoisomers for each substitution:  (Sp)-CAMPS,’ (Rp)- 
CAMPS, (S~)-CAMPN(CH~)~,  and  (Rp)-cAMPN(CH3), (see 
Fig. 1). 
De Wit et al. (4) were first to report on the differential 
activation of CAMP-dependent protein kinase type I from 
rabbit muscle  by (Sp)-CAMPS  and (Rp)-CAMPS. They showed 
that binding of the S p  isomer to  the enzyme yields complete 
activation of the  protein kinase. In  contrast,  the Rp isomer 
could not  activate  the enzyme by more than lo%, although  it 
occupied the enzyme by more than 90%. O’Brian et al. (6) 
subsequently  reported  similar  data for CAMP-dependent pro- 
tein kinase type I1 from rabbit muscle. 
Recently we have used these compounds to reveal the 
activation  mechanism of the cell surface cAMP receptor from 
the cellular  slime mold Dictyosteliurn discoideurn ( 5 ) ,  and  the 
mechanism of enzymatic  hydrolysis of CAMP by phosphodi- 
esterase (8). During  these  studies we observed that  the  prep- 
arations of the Rp isomers of CAMPS  and  CAMPN(CH~)~ 
contained  traces of their Sp isomers (2-676) and  CAMP, which 
might be responsible for the  activities of the Rp preparations 
reported previously (4, 6, 9). After  extensive  purification we 
The abbreviations used are: CAMPS, adenosine 3’,5’-monophos- 
phorothioate; cAMPN(CH3)2, adenosine 3’,5’-monophosphodimeth- 
ylamidate; MES, 4-morpholineethanesulfonic acid. 
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Competitive CAMP Antagonists 10021 
S~-CAMPN(CH,), OH 
FIG. 1. Structures of the cAMP analogs with modified exo- 
cyclic  oxygen atoms. 
observed that  the Rp isomers of CAMPS  and  cAMPN(CH& 
no longer  have activating  properties.  Since  these  compounds 
bind to the cAMP receptor in a competitive manner with 
respect to  cAMP  it was  suggested that  these  compounds  are 
antagonists of CAMP. 
In  the  present work we have  investigated  the agonistic and 
antagonistic  activities of the highly purified preparations of 
the S p  and Rp isomers of CAMPS  and  cAMPN(CH& for  four 
CAMP-dependent proteins: the cell surface cAMP receptor 
from D. discoideum, CAMP-dependent protein  kinase  type I 
from beef heart,  type I1 from  rabbit muscle, and  type D from 
D. discoideum. The  results show that  antagonists  are  present 
among  these four  derivatives. 
EXPERIMENTAL PROCEDURES 
Muteri~k-[[y-~~P]ATP was obtained from New England Nuclear 
and  the radioimmunoassay kit from the Radiochemical Centre (Buck- 
inghamshire,  United  Kingdom).  Sephacryl s-300 was purchased from 
Pharmacia  (Uppsala,  Sweden); Leu-Arg-Arg-Ala-Ser-Leu-Gly 
(kemptide) was from Sigma. 
The stereoisomers of CAMPS were synthesized as described in Ref. 
7. The  synthesis of the isomers of cAMPN(CH3)Z  will  be described 
elsewhere. The compounds were purified by high performance liquid 
chromatography (5). After purification, the Rp isomers are free of 
detectable levels of the Sp isomers or  cAMP (< 0.1%). 
Methods-The CAMP-mediated cGMP response was measured in 
aggregative D. discoideum, NC-I(H), cells (10). Briefly, 50-pl cell 
suspensions were stimulated with  10 ~1 of cAMP  or derivative. The 
reaction was terminated  after 10 s by the addition of 50 p1 of perchloric 
acid. cGMP was measured in the neutralized  lysates by means of a 
radioimmunoassay. 
CAMP-dependent protein kinase  type  D (holoenzyme) was isolated 
from aggregative D. discoideurn, AX-2, by  gel filtration of a cytosolic 
cell fraction  on  Sephacryl  S-300 as described in Ref. 11. 
CAMP-dependent protein kinase  type I from beef heart was isolated 
as described in Ref. 12 using  one  DEAE-chromatography  step.  CAMP- 
dependent protein kinase type I1 from rabbit muscle was obtained 
from Sigma. Protein kinase  activity was measured  (13) in a  reaction 
mixture  (60 p1) containing 50 mM MES buffer (pH 6.5),  5 mM MgClZ, 
0.5 mM EGTA, 10 mM NaF, 2.5 mM dithiothreitol, 20 p~ kemptide, 
0.2 mM [Y-~'P]ATP (2 Bq/pmol), enzyme, and cyclic nucleotides. The 
reaction (30 "C) was started by the addition of 30 pl  of enzyme, and 
terminated  after 10 min by the addition of 600 p1 of a 50% slurry of 
Dowex 1-X2 in 30% acetic acid. After equilibration for 1 h, samples 
were centrifuged for 2 min a t  10,000 X g. The radioactivity in 175 pl 
of the  supernatant was determined. 
RESULTS 
The Cell Surface CAMP Receptor from D. discoideum- 
Binding of cAMP  to  the cell surface  cAMP receptor of the 
cellular  slime mold D. discoideum induces  several  responses, 
of which an  intracellular  accumulation of cGMP  is  the  first 
response observed (for review on signal transduction in D. 
discoideum see Refs. 14 and 15). cGMP levels reach a  peak at  
10 s after  stimulation  and  prestimulated levels are recovered 
within about 30 s. The pace of the cGMP response is the 
same for different  cAMP analogs (10). 
The  cGMP response  induced  by cAMP  and  the four deriv- 
atives with modified exocyclic oxygen atoms  are shown  in Fig. 
2 A ;  three  compounds  are active, and two are inactive. Linear 
curves arise when these  data  are  replotted according to  Eadie 
and Hofstee (Fig. 2, C and D). The intersections with the 
ordinate reveal that  CAMP,  (Sp)-CAMPS,  and (Sp) -  
cAMPN(CH& induce about  the  same maximal  response. The 
slopes of these curves represent  the K, (concentration which 
induces half-maximal  stimulation);  this yields 14 nM for 
O* O k  
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FIG. 2. Agonistic and antagonistic activities of exocyclic 
oxygen-modified cAMP analogs for CAMP-mediated cGMP 
response in D. discoideum. A, D. discoideum cells were stimulated 
with different  concentrations of cAMP (+), (5'~)-CAMPS (O), (Rp)- 
CAMPS (O), (Sp)-cAMPN(CH& (A), or (R~) -CAMPN(CH~)~  (A). 
Cells were lysed at  10 s after stimulation and cGMP levels were 
measured radioimmunologically. B. D. discoideum cells were prein- 
cubated for 30 s with  different  concentrations of (Rp)-CAMPS (0), 
(Rp)-cAMPN(CH& (A). Then 50 nM cAMP was added, cells were 
lysed 10 s later, and  cGMP levels were measured. C and D, Eadie- 
Hofstee  plots of the  data of A.  AV is the increase of cGMP levels 
over basal levels, and A is the concentration of the nucleotides. The 
intersections  with the ordinates  are the maximal response; the slopes 
equal -Km. Symbols are described in A.  E and F, inspection for 
competitive antagonism of (Rp)-cAMPS. D. discoideum cells were 
preincubated for 30 s with three concentrations of (&)-CAMPS (0, 
2.5,  8.33 p ~ ) .  Then cells were stimulated with different  cAMP  con- 
centrations (0, 10, 20,30, 40, and 100  nM); cells were lysed 10 s later 
and  cGMP levels were measured. A Lineweaver-Burk plot of the  data 
is shown in E; preincubation  without (O), or with 2.5 p~ (0), or 8.33 
p~ (A) (Rp)-cAMPS. A Dixon plot of the same data is shown in F; 
response to 100 nM (O), 40 nM (0) ,30 nM (A), or 20 nM (A) CAMP. 
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10022 Competitive CAMP Antagonists 
CAMP, 0.78 ptM for  (Sp)-cAMPS,  and 2.8 pM for (Sp) -  
The  compounds  (Rp)-CAMPS  and  (Rp)-cAMPN(CH3)2  do 
not induce  a cGMP  response,  although  it  has been  shown that 
they  bind  to  the cell surface  cAMP  receptors at micromolar 
concentrations ( 5 ) .  To  test   the compounds for antagonistic 
properties, the cells were mixed with the Rp stereoisomers 
and  then  stimulated  with 50 nM CAMP.  This reveals  (Fig. 2B) 
that  the analogs antagonize  the  stimulating  activity of CAMP. 
Half-maximal inhibition (Icso) occurs at 4 p~ (Rp)-CAMPS 
and  at  about 100 p~ (Rp)-cAMPN(CH&. 
Since these compounds are investigated with whole cells 
they may inhibit the CAMP-mediated cGMP response at  a 
site  distinct  from  the  cAMP  receptor.  Therefore,  it  had  to  be 
established  that  the  Rp  compounds  are competitive antago- 
nists of CAMP. Cells were stimulated by different cAMP 
concentrations in the presence of different  concentrations of 
(Rp)-CAMPS. The Lineweaver-Burk plot (Fig. 2 E )  and the 
Dixon plot (Fig. 2F)  indicate  that  (RP)-CAMPS  is a competi- 
tive antagonist of CAMP.  The KI values  for the Rp isomers 
can be  calculated  from the ICs0 values obtained  in Fig. 2B by. 
using  the  equation 
cAMPN(CH3)2. 
where K,  is the  activation  constant of cAMP (14 nM) and A 
is  the  concentration of cAMP (50 nM). This yields KI = 0.9 
p~ for (Rp)-CAMPS  and KI = 22 p~ for  (Rp)-cAMPN(CH3)2. 
K,  values can also be derived from a Dixon plot (Fig. 2F)  
which yields KI = 0.8 p~ for (Rp)-CAMPS. 
These data demonstrate (Table I) that (Sp)-CAMPS and 
(Sp)-cAMPN(CH3)2  are full agonists of cAMP for the  induc- 
tion of a cGMP response in D. discoideum. (Rp)-CAMPS  and 
(Rp)-cAMPN(CH3)2  are competitive  full antagonists of 
CAMP.  The ffects of the  derivatives  with  the CAMP-depend- 
ent  protein  kinases  type  I, 11, and D were investigated in a 
similar  manner. 
CAMP-dependent Protein Kinuses Type I and Type 11 from 
Mammalian Cells-The transfer of 32P from [ Y - ~ ~ P ] A T P   t o  
kemptide catalyzed by protein kinase type I1 from rabbit 
muscle in the presence of cAMP and/or the derivatives is 
shown in Fig. 3. CAMP,  (Sp)-CAMPS,  and  (Sp)-cAMPN(CH3)2 
stimulate  protein  kinase type 11, while both Rp isomers are 
inactive. An Eadie-Hofstee  plot of these  data (Fig. 3, C and 
D )  yields a nonlinear concave upwards curve, which may 
suggest  negative  cooperativity. The  analog  (Sp)-CAMP- 
N(CH& induces about  the  same  maximal response as  cAMP 
(intersection with an ordinate); the maximal activation in- 
duced by (Sp)-CAMPS is significantly less (activation  up  to 
85%). This  has also  been  shown  previously by O'Brian et al. 
(6). The  apparent  activation  constants  (concentrations which 
induce half-maximal stimulation of protein  kinase  activity) 
are  about 0.4 pM for CAMP, 1.8 pM for (Sp)-CAMPS,  and 7.0 
MM for (Sp)-cAMPN(CH3)2. 
The two analogs, (Rp)-cAMPS and (RP)-CAMPN(CH~)~, 
which do  not  stimulate  protein  kinase  type I1 were tested for 
antagonistic activities; the enzyme was incubated with 2 p~ 
cAMP  and  different  concentrations of the Rp isomers (Fig. 
3B).  The  stimulating effect of cAMP is antagonized by  (Rp)- 
CAMPS with an IC, of about 16 p ~ .  The analog (Rp)- 
c A M P N ( C H ~ ) ~  has  much less antagonizing activity with  an 
estimated ICbo of = 450 pM. 
To  test  whether  these compounds are competitive antago- 
nists of cAMP  is complicated by the  fact  that  activation of 
protein kinase type I1 does not follow Michaelis-Menten 
kinetics; this  leads  to  nonlinear  Eadie-Hofstee  plots (Fig. 3,  
C and D) and now linear Lineweaver-Burk and Dixon plots 
(data  not  shown).  The  activity of the enzyme in  the presence 
of different concentrations of cAMP and (&)-CAMPS are 
shown in Fig. 3, E and F. The dose-response curves run 
parallel, which is  the  first  indication for  competitive antago- 
nism. In a Hill plot of these  data (Fig. 3F)  it  was assumed 
that the enzyme has the same AV,.. in the absence and 
presence of the  antagonist  (this  is a prerequisite  for  compet- 
TABLE I 
Properties of CAMP and CAMP  derivatives for four CAMP receptor proteins 
CSR D" CAK Ib CAK IIb CAK Db 
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FIG. 3. Agonistic and antagonistic activities of exocyclic 
oxygen-modified cAMP analogs for CAMP-dependent protein 
kinase  type 11. A, the  transfer of 32P from [y3’P]ATP  to kemptide 
catalyzed by CAMP-dependent protein kinase type I1 from rabbit 
muscle was measured in the presence of different concentrations of 
(A), or (Rp)-cAMPN(CH3)2 (A). B, protein kinase activity in the 
presence of 2 PM cAMP and different concentrations of (&)-CAMPS 
(O), or (Rp)-cAMPN(CH& (A). C and D, Eadie-Hofstee plots of the 
data of A. In AV the protein  kinase activity in the absence of cyclic 
nucleotide is subtracted. Symbols are as described in A. E and F, 
inspection for competitive antagonism of (Rpl-cAMPS. Activation of 
protein kinase type I1 by different cAMP concentrations was mea- 
sured  in the absence (+), or in the presence of 2.5 PM (m), 14 p~ (U), 
or 50 PLM (X )  (Rp)-CAMPS. Dose-response curves are shown in E. A 
Hill plot from the same data is shown in F; AV,.. is the maximal 
increase of activity induced by cAMP (intersection with ordinate  in 
C). 
CAMP (+), (Sp)-cAMPS (O), (Rp)-cAMPS (O), (Sp)-cAMPN(CH& 
itive  antagonism).  The four lines  in  the  Hill  plot  have  essen- 
tially  identical slopes (Hill coefficient,  n = 0.8). This  strongly 
suggests that the compound (Rp)-CAMPS is a competitive 
antagonist of cAMP for protein kinase type 11. The data 
indicate an  apparent KI = 3.7 p~ for  (Rp)-CAMPS  and KI = 
75 PM for  (RP)-CAMPN(CH~)~.  The  results  with CAMP-de- 
pendent  protein  kinase  type I1 indicate  (Table  I)  that (Sp)- 
cAMPN(CH&  is a full agonist of CAMP,  (Sp)-CAMPS  is a 
partial agonist, (Rp)-~AMPN(CH3)z is an antagonist, and 
(Rp)-CAMPS  is a competitive full antagonist. 
The same experiments were done with CAMP-dependent 
protein  kinase type I from beef heart, which yields qualita- 
tively similar, but quantitatively different results (data not 
shown).  The  compounds  CAMP,  (Sp)-CAMPS,  and (Sp) -  
cAMPN(CH&  activate  the enzyme with  apparent  activation 
constants K0.5 = 28 nM for CAMP, KO.5 = 1.0 p~ for (Sp)- 
CAMPS,  and KO, = 2.2 p~ for (S~)-CAMPN(CH~)~.  In  contrast  
to protein  kinase  type 11, the  compound  (Rp)-cAMPN(CH3)2 
is  also  stimulatory  in  protein  kinase  type I with an  estimated 
= 1 mM. Eadie-Hofstee plots are nonlinear (concave 
0 10 20 
6 0:s t i s  
0 0’s 1 
0 0’05 01 
JV/A “10.’ 
FIG. 4. Agonistic activities of exocyclic oxygen-modified 
cAMP derivatives for CAMP-dependent protein kinase type 
D. A, partially purified protein kinase was isolated from D.discoideum 
cells. Protein kinase activity was measured in the presence of different 
concentrations of cAMP (+), (SF)-CAMPS (O), (Rp)-CAMPS (01, 
(Sp)-cAMPN(CH& (A), or (Rp)-cAMPN(CH& (A). B, Eadie-Hof- 
stee plot of the same data. The abscissas are scaled in such a way that 
the four curves converge into  a single point. The fact that +, 0, and 
A are part of the same curve indicates that these compounds induce 
the same maximal response. Symbols are as described in A. 
downwards), which suggests positive cooperativity. This is 
also  suggested by the  Hill coefficient n = 1.8. cAMP  and (Sp) -  
CAMPS  induces  about  the  same maximal  activity; the maxi- 
mal activity induced by (Sp)-cAMPN(CH3)2  is significantly 
less (75% of the maximum of CAMP). The analog (&)- 
CAMPS  antagonizes  the  stimulatory effect of 50 nM CAMP 
with  an ICso = 18 p ~ .  Experiments with  different concentra- 
tions of cAMP  and  (&)-CAMPS (analogous to  the  experiment 
shown in Fig. 3, E and F )  indicate that (&)-CAMPS is a 
competitive antagonist of cAMP with an  apparent  Kr = 8 p ~ .  
The  results show (Table  I)  that  (Sp)-CAMPS is a full agonist 
of cAMP for protein  kinase type I, (SF)-cAMPN(CH& is a 
partial  agonist,  and  (&)-CAMPS  is a  competitive full antag- 
onist.  The compound (Rp)-cAMPN(CH&  is  at  least a partial 
agonist,  since  half-maximal  stimulation  is observed a t  1 mM 
(the  highest  concentration  investigated). 
CAMP-dependent Protein Kinase from D. discoideum-Re- 
cently a CAMP-dependent protein  kinase  has been isolated 
from the cellular  slime mold D. discoideum (type D) (11, 16, 
17). CAMP, (Sp)-CAMPS, and (Sp)-cAMPN(CH& activate 
this enzyme (Fig. 4A). Eadie-Hofstee  plots show that  these 
compounds induce  approximately the  same maximal activa- 
tion of the enzyme (Fig. 4B). The compound (Rp)-cAMPS is 
also stimulatory, but its maximal activation is only 52% of 
the maximum induced by CAMP. Eadie-Hofstee plots are 
linear, which  suggests the  absence of cooperativity. The  acti- 
vation constants are 150 nM for CAMP, 1.9 p~ for (Sp) -  
CAMPS, 11.3 for (Itp)-CAMPS,  and 3.2 p~ for (Sp)-  
The  compound  (Rp)-cAMPN(CH3)2  does not activate  the 
enzyme  up to 100 p~ (Fig. 4A), and it also  does not  inhibit 
the stimulation by 0.5 p~ cAMP (data not shown). It has 
been  shown previously (18) that  this compound  competes  very 
poorly  with the  binding of [3H]cAMP  to  the regulatory sub- 
unit of the enzyme. This suggests that   (RP)-CAMPN(CH~)~ is 
inactive. 
The results show (Table I) that (SF)-CAMPS and (Sp)-  
cAMPN(CH&  are full agonists of cAMP for protein kinase 
type D, (&)-CAMPS  is a partial  gonist,  and ( I t p ) -  
cAMPN(CH,), is inactive. 
cAMPN(CH3)Z. 
DISCUSSION 
In previous experiments  on  the  interaction of cAMP deriv- 
atives  with  cAMP  receptor  proteins  it was  shown that  essen- 
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10024 Competitive cAMP  Antagonis s 
tially  all  derivatives that bind to  the  receptors also activate 
these receptors (4,5).  Studies  on  the  action of the derivatives 
with modified exocyclic oxygen atoms revealed that these 
compounds bind to  the  receptors,  but  that some of them do 
not fully activate the receptors (4-6). This suggests that 
binding of  CAMP to  the  receptor  and  activation of the  receptor 
are two distinct processes in a concerted reaction. Binding of 
cAMP  to a receptor involves atoms or atom groups distributed 
all  over the  cAMP  structure, whereas activation requires an 
additional  interaction between the  receptor  protein  and  the 
phosphate moiety of cAMP (4, 5 ) .  At least three atomic 
interactions  are possible  between the receptor and  the  phos- 
phate moiety (i) a charge-charge interaction between a posi- 
tively charged amino acid side chain and the negatively 
charged phosphate moiety (ii) a  polar interaction (hydrogen 
bond) between one or both of the exocyclic oxygen atoms of 
cAMP and the receptor protein, and (iii) a covalent bond 
between the  phosphorus  atom  and  the receptor protein (19). 
A charge-charge interaction  is excluded by the  results with 
the noncharged analog  (Sp)-cAMPN(CH&. 
The proposed activation  mechanisms led us  to hypothesize 
that  an  analog  with a modified exocyclic oxygen atom may 
still  bind  to  the receptor, but is no longer able  to provide the 
activating  interaction.  Such a  derivative would be the much 
sought  after  antagonist of cAMP  acting specifically a t  cAMP 
receptor proteins. 
In  this  study we have investigated  the  antagonistic  activities 
of four derivatives  in which one of the exocyclic oxygen atoms 
is replaced  by either a sulfur  atom or a dimethylamino  atom 
group, (Sp)-CAMPS, (&)-CAMPS, (Sp)-cAMPN(CHJ2 and 
(Rp)-cAMPN(CH3)2. These analogs were tested with four 
CAMP-dependent proteins:  the cell surface receptor on  intact 
D. discoideum cells which induces an intracellular cGMP 
response, CAMP-dependent protein  kinase  type I from beef 
heart,  type I1 from rabbit muscle, and  type D from D. discoi- 
deum. 
The  results show that  (Sp)-CAMPS  and  (Sp)-CAMP- 
N(CH& are (mostly full) agonists of CAMP. (Rp)-CAMPS 
does not  activate cell surface  receptors, protein  kinase  type I 
and  type 11. Previously  a small  activation  (about 10%) of type 
I and  type I1 was observed (4, 6), which now appears  to be 
due to  impurities of (Sp)-CAMPS  (about 2%) and  cAMP (less 
than 0.1%). These  impurities  (as well as  impurities  in  (Rp)- 
cAMPN(CH& were removed in  the  preparations used in  the 
present study, and in previous reports on the cell surface 
cAMP  receptor (5,20). 
In the present work we show that (&)-CAMPS is com- 
pletely  inactive and  that  it  inhibits  the  stimulating effect of 
cAMP in  a  competitive way. The  inhibition  constants of (Rp)- 
CAMPS for the receptor proteins are similar to respective 
binding affinities of the analog for the receptors (4, 5, 8). 
Therefore, we conclude that  (Rp)-CAMPS  binds  to  the  CAMP- 
binding  sites,  but  that  the  analog is not  able  to  activate  the 
receptor; (Ep)-CAMPS is a competitive  full antagonist of 
cAMP acting at  CAMP-binding sites from the cell surface 
cAMP receptor, and  protein  kinase  type I and  type 11. Inter- 
estingly,  (&)-CAMPS partially  activates  protein  kinase type 
D. This  protein  kinase from D. discoideum differs  from mam- 
malian  protein  kinases by molecular weight, subunit compo- 
sition,  and  kinetic  properties of CAMP-binding (11, 18). 
Nevertheless, the regulatory subunit can combine with the 
purified catalytic  subunit  from  protein  kinase  type I or type 
I1 (21). 
The analog (Rp)-cAMPN(CH3)* is an antagonist for the 
cell surface  cAMP  receptor  and for protein  kinase type 11. In 
contrast,  the  analog is an agonist  for protein kinase  type I, 
and inactive  for protein  kinase  type D. We  have not  investi- 
gated the competitive nature of this  antagonist, because the 
compound  acts only at high concentrations. 
Thus, we have shown that (&)-CAMPS is a competitive 
antagonist at micromolar concentration,  acting specifically at  
CAMP-binding sites. However, the compound cannot be  used 
without  any  precautions.  First,  (Rp)-CAMPS does not  antag- 
onize all CAMP-dependent proteins. CAMP-dependent pro- 
tein  kinase from D. discoideum is activated  up  to 50% by the 
analog, and the analog is the most potent activator of p- 
galactosidase synthesis  in Escherichia coli (22). Second, the 
analog binds to mammalian phosphodiesterase, but is not 
hydrolyzed by the enzyme (8). Therefore, phosphodiesterase 
is partially inhibited, which allows endogenous cAMP to 
accumulate,  and  to compete with  (Rp)-CAMPS for binding  to 
protein kinase. Despite  these complicating  properties, recent 
reports  on cellular  slime mold chemotaxis (20) and  on glyco- 
genolysis (23) show the usefulness of the compound. 
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